Celldex Therapeutics Inc. (CLDX)

2.36
NASDAQ : Health Technology
Prev Close 2.37
Day Low/High 2.22 / 2.37
52 Wk Low/High 2.01 / 11.62
Avg Volume 134.60K
Exchange NASDAQ
Shares Outstanding 15.02M
Market Cap 35.59M
EPS -14.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Weak On High Volume: Celldex Therapeutics (CLDX)

Weak On High Volume: Celldex Therapeutics (CLDX)

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a weak on high relative volume candidate

Strong On High Relative Volume: Celldex Therapeutics (CLDX)

Strong On High Relative Volume: Celldex Therapeutics (CLDX)

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a strong on high relative volume candidate

Celldex Therapeutics (CLDX) Is Today's Dead Cat Bounce Stock

Celldex Therapeutics (CLDX) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "dead cat bounce" (down big yesterday but up big today) candidate

Biotech Stock Mailbag: More Duchenne Drama, CAR-T Trouble, ASCO '15 Rewind

Biotech Stock Mailbag: More Duchenne Drama, CAR-T Trouble, ASCO '15 Rewind

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Heavy Early Morning Activity On Celldex Therapeutics (CLDX)

Heavy Early Morning Activity On Celldex Therapeutics (CLDX)

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a pre-market mover with heavy volume candidate

ASCO '15 Report Card: Grading Biotech and Drug Stocks at Cancer Drug Confab

ASCO '15 Report Card: Grading Biotech and Drug Stocks at Cancer Drug Confab

The ASCO winners include Oncothyreon, ImmunoGen and Celldex Therapeutics, while Puma, Clovis and Bristol-Myers lost ground.

ASCO '15: Celldex Immunotherapy Maintains Survival Benefit for Recurrent Brain Tumor Patients

ASCO '15: Celldex Immunotherapy Maintains Survival Benefit for Recurrent Brain Tumor Patients

Celldex is meeting with FDA to determine if the Rintega data from the recurrent brain tumor study known as ReACT are strong enough to file for accelerated approval.

Biotech Stock Mailbag: ASCO Preview, CAR-T stocks, MannKind, Hate Mail!

Biotech Stock Mailbag: ASCO Preview, CAR-T stocks, MannKind, Hate Mail!

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Celldex Therapeutics To Present Data From The ReACT Study At 2015 ASCO Annual Meeting

Celldex Therapeutics To Present Data From The ReACT Study At 2015 ASCO Annual Meeting

--Additional presentations on the METRIC study evaluating glembatumumab vedotin and the Phase 1/2 CDX-301 study--

Jumpstart ASCO '15 With This Quick List of Hot Research Abstracts

Jumpstart ASCO '15 With This Quick List of Hot Research Abstracts

The American Society of Clinical Oncology has provided public access to 5,000 cancer drug trial research abstracts ahead of its big annual meeting. These will be some highlights for investors.

Biotech Stock Mailbag: Biotech Bull So Insanely Good It Will Make You Forget Week's Pain

Biotech Stock Mailbag: Biotech Bull So Insanely Good It Will Make You Forget Week's Pain

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Today's Dead Cat Bounce Stock Is Celldex Therapeutics (CLDX)

Today's Dead Cat Bounce Stock Is Celldex Therapeutics (CLDX)

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "dead cat bounce" (down big yesterday but up big today) candidate

Nasdaq Backs Off Record High as Biotech Drags Markets Lower

Nasdaq Backs Off Record High as Biotech Drags Markets Lower

Friday's record run was cut short on Monday as the S&P 500 and Nasdaq backed off of their closing highs.

Biotech Drags on Stocks; Crude Oil Drops Below $57

Biotech Drags on Stocks; Crude Oil Drops Below $57

Stocks drift lower on Monday afternoon as the Nasdaq gaps from record highs set on Friday.

Celldex Therapeutics (CLDX) Showing Signs Of Being Water-Logged And Getting Wetter

Celldex Therapeutics (CLDX) Showing Signs Of Being Water-Logged And Getting Wetter

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

Stock Index Tracking Red-Hot Cancer Immunotherapy Field Launched

Stock Index Tracking Red-Hot Cancer Immunotherapy Field Launched

The Loncar Cancer Immunotherapy Index (LCINDX) tracks biopharma companies developing (or already marketing) drugs which use the body's own immune system to target and kill cancer cells.

Biotech Stocks at a Crossroad

Own them, or take something off the table?

Stock To Watch: Celldex Therapeutics (CLDX) In Perilous Reversal

Stock To Watch: Celldex Therapeutics (CLDX) In Perilous Reversal

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate

TheStreet Quant Rating: D- (Sell)